Condiciones de salud que alcachofa puede ayudar a apoyar.
Artichoke leaf extract (ALE) has been studied in RCTs for functional dyspepsia and IBS, showing improvements in abdominal symptoms. It appears in multi-herb preparations with established clinical evidence. ALE is also listed among botanicals with demonstrated clinical benefit for functional GI disorders in authoritative reviews.
Artichoke leaf extract (ALE) has been shown in clinical trials to reduce upper gastrointestinal symptoms including heartburn and epigastric discomfort. A 6-week RCT in 247 patients with functional dyspepsia demonstrated significantly greater overall symptom improvement with ALE (960 mg/day) versus placebo. Post-marketing surveillance studies with 320–640 mg three times daily reported nausea, abdominal pain, and fullness resolved in over 70% of patients. Choleretic action—stimulating bile flow—is considered the primary mechanism, improving fat digestion and reducing reflux-type symptoms.
Artichoke leaf extract contains one of the highest polyphenol contents among vegetables, with chlorogenic acid, cynarin, caffeic acid, luteolin, and apigenin all exhibiting potent free-radical scavenging. In vitro and preclinical studies confirm ALE reduces MDA, lipid peroxidation, and ROS, and upregulates SOD, GPx, and CAT. Human and ex vivo clinical data support meaningful antioxidant activity after oral ingestion.
Artichoke (Cynara scolymus) leaf extract reduces LDL cholesterol, increases HDL, and improves endothelial function. RCTs confirm its lipid-modifying and vascular anti-inflammatory effects. Artichoke's cynarin and luteolin inhibit cholesterol synthesis and improve bile acid excretion, reducing atherogenic lipid burden on arterial walls.
A 2025 meta-analysis of multiple RCTs found artichoke supplementation significantly reduced systolic BP (WMD −2.49 mmHg) and diastolic BP (WMD −1.53 mmHg). An earlier meta-analysis of 8 RCTs (n=512) also evaluated blood pressure specifically. Mechanistically, chlorogenic and caffeoylquinic acids exhibit vasodilatory and ACE-inhibitory properties.
A meta-analysis of nine RCTs found artichoke supplementation significantly reduced fasting blood glucose (WMD: −5.28 mg/dL, p=0.005). Chlorogenic acid inhibits glucose-6-phosphatase and modulates gluconeogenesis, while inulin slows gastric emptying and glucose absorption. A subgroup analysis showed artichoke alone (not co-supplemented) also significantly reduced HOMA-IR.
Artichoke leaf extract (ALE) reduces total cholesterol, LDL-C, and triglycerides in systematic reviews and RCTs. A 2024 double-blind RCT in 90 adults showed significant TC, LDL-C, and TG reductions versus placebo at 6 and 12 weeks. Typical doses are 500–1,800 mg/day standardized dry extract.
Artichoke leaf polyphenols—particularly luteolin and cynaropicrin—inhibit NF-κB signaling and reduce pro-inflammatory cytokines. A 2024 meta-analysis found artichoke supplementation significantly reduced hs-CRP. An ex vivo clinical trial showed that human serum enriched with ALE metabolites attenuated inflammation in hepatocytes and chondrocytes.
Artichoke (Cynara scolymus) has been shown to inhibit digestive enzymes including pancreatic lipase, alpha-amylase, and alpha-glucosidase in preclinical studies, and to stimulate bile production which is required for fat digestion. These effects on the enzymatic environment of digestion are supported by mechanism studies and indirectly by clinical dyspepsia trials.
Artichoke leaf extract has well-documented choleretic (bile-stimulating) activity confirmed in a randomized, placebo-controlled, double-blind crossover study (n=20) showing 127–151% increase in bile secretion. Active compound cynarin stimulates bile production. A 247-participant double-blind study found it more effective than placebo for digestive symptoms linked to poor bile flow.
Artichoke leaf extract (ALE) is documented in the German Commission E and European Medicines Agency monographs for traditional use in relieving digestive complaints related to sluggish bile flow. Clinical and animal studies show ALE significantly increases bile secretion (choleresis), with a double-blind crossover study in 20 subjects demonstrating a 127–151% increase in intra-duodenal bile secretion after administration of standardized extract. Active constituents cynarin and chlorogenic acid drive hepatocyte bile production.
Artichoke is a significant source of inulin-type fructans and fructooligosaccharides, classified as prebiotics. An in vitro SHIME model study with artichoke aqueous dry extract demonstrated bifidogenic effects and increased production of health-related microbial metabolites. Artichoke's choleretic action also promotes bile acids in the colon, supporting beneficial intestinal flora.
Artichoke polyphenols—chlorogenic acid, luteolin, cynarin—are potent antioxidants that may slow age-related oxidative and inflammatory damage. An ex vivo clinical trial demonstrated ALE metabolites protect human hepatocytes from lipotoxic stress, reduce adipocyte hyperplasia, and exert chondroprotective effects, all relevant to aging-related organ deterioration. The aging population context underpins several ALE trials targeting metabolic and inflammatory disease.
Artichoke (Cynara scolymus) leaf extract contains cynarin and chlorogenic acid that stimulate bile secretion to improve fat digestion and inhibit cholesterol synthesis. Clinical evidence shows artichoke extract significantly reduces LDL cholesterol, improves liver function, and modulates lipid metabolism, with mechanistic support for weight management through bile acid and lipid regulation.
Multiple RCTs and meta-analyses confirm artichoke leaf extract reduces total cholesterol, LDL, and triglycerides and raises HDL in hypercholesterolemic adults. A 2025 meta-analysis of multiple RCTs found significant reductions in total cholesterol (WMD −12.29 mg/dL) and LDL. One study in metabolic syndrome patients also showed improved carotid intima-media thickness after six months of ALE.
Artichoke leaf extract (ALE) has moderate clinical evidence for functional dyspepsia and IBS, including several RCTs. It exerts prokinetic and anti-inflammatory effects via cynarin and chlorogenic acid. A large observational study (n=279) showed significant IBS symptom improvement with ALE. It is also a component of the Iberogast combination formula studied in IBS trials.
A meta-analysis of nine RCTs demonstrated that artichoke supplementation significantly reduced HOMA-IR (WMD: −0.52, p=0.002) in a subgroup using artichoke alone. Chlorogenic acid modulates gluconeogenic enzymes and luteolin supports insulin receptor signaling. A 2024 RCT also showed improved insulin sensitivity markers with artichoke/bergamot combination.
Artichoke leaf extract (Cynara scolymus) demonstrates antioxidant, choleretic, and hepatoprotective effects validated in both animal studies and human RCTs. A double-blind RCT in 60 NASH patients showed significant improvement in liver enzymes (ALT, AST) and lipids with 2700 mg/day extract. A 2018 RCT in 100 NAFLD patients showed increased hepatic blood flow and reduced liver enzymes, bilirubin, and triglycerides with 600 mg/day. Traditional use as a liver tonic and cholagogue dates back centuries in Mediterranean herbal medicine.
Artichoke has been specifically studied in metabolic syndrome populations across multiple RCTs. A 2025 meta-analysis of 21 RCTs (n=1,372) including metabolic syndrome participants found significant reductions in BMI, waist circumference, blood pressure, total cholesterol, LDL, and fasting blood glucose. A 6-month RCT in 100 metabolic syndrome patients found improvements in lipids, liver health, and carotid intima-media thickness.
Artichoke leaf extract has been shown in multiple clinical studies to reduce nausea as part of the functional dyspepsia symptom complex. ESCOP monographs list nausea and vomiting as indications. Post-marketing surveillance studies with 320–640 mg ALE three times daily found nausea resolved among the majority of patients at 2 months.
Artichoke leaf extract has been shown in a meta-analysis of 9 RCTs (n=702) to significantly reduce triglycerides (WMD = −9.2 mg/dL, p=0.011) in addition to lowering total and LDL cholesterol. Active components include cynarin, chlorogenic acid, and luteolin, which modulate hepatic lipid metabolism.
Artichoke leaf (Cynara scolymus) contains cynarin and cynaropicrin, which stimulate liver bile production and excretion, supporting hepatic detoxification. A 2023 PMC study demonstrated that artichoke leaf extract reduced ALT, AST, and SOD activity in CCl4-exposed animals, suggesting liver protective and regenerative properties.
Artichoke has a long traditional use as a bitter herb that stimulates appetite via its bitter sesquiterpene lactones (cynaropicrin) acting on digestive secretions. The German Commission E and ESCOP monographs reference appetite stimulation through bitterness-induced digestive enzyme and bile secretion. Clinical evidence is indirect—from dyspepsia and digestive studies—rather than from dedicated appetite trials.
Artichoke (Cynara scolymus) leaf extract is a traditional European digestive remedy that promotes bile secretion (cholagogue) and improves GI motility. German Commission E and ESCOP recognize artichoke leaf for dyspeptic complaints including constipation associated with digestive insufficiency. A placebo-controlled RCT in 244 dyspepsia patients found artichoke leaf extract significantly improved IBS symptoms including bowel function.
Artichoke (Cynara scolymus) is a recognized European hepatic remedy that stimulates bile flow (cholagogue effect), supporting biliary excretion of conjugated estrogen metabolites—the Phase III elimination step in liver-based hormone detoxification. Cynarin, its principal active compound, has documented liver-protective and choleretic effects recognized in the German Commission E and ESCOP monographs.
Artichoke has been used as a diuretic in traditional European medicine since Roman times. The EMA HMPC monograph and European Pharmacopoeia (Cynarae folium) list 'traditionally used to promote urinary and digestive elimination functions.' No dedicated human RCTs measuring diuretic output or edema specifically are available.
Volver